Do you offer enasidenib with azacitadine in AML with an IDH2 mutation for patients ineligible for intensive induction chemotherapy?  

I typically do not give enasidenib with azacitidine upfront for patients with AML with IDH2 mutation and ineligible for intensive induction chemotherapy. Based on the results of the VIALE-A study (DiNardo et al, NEJM 2020), I usually give venetoclax with azacitidine to those patients. In addition to...

I would not give this outside of a clinical trial. An interesting trial would be enasidenib added to azacitidine plus venetoclax (which I agree is now the standard based on VIALE A). The data upfront is dissuading, as are the Phase 3 IDHentify trial data which showed the absence of primary endpoint ...